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Diabetes Mellitus Secondary to 
Cushing’s Disease
Mattia Barbot*, Filippo Ceccato and Carla Scaroni
Endocrinology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy
Associated with important comorbidities that significantly reduce patients’ overall 
wellbeing and life expectancy, Cushing’s disease (CD) is the most common cause of 
endogenous hypercortisolism. Glucocorticoid excess can lead to diabetes, and although 
its prevalence is probably underestimated, up to 50% of patients with CD have varying 
degrees of altered glucose metabolism. Fasting glycemia may nevertheless be normal 
in some patients in whom glucocorticoid excess leads primarily to higher postpran-
dial glucose levels. An oral glucose tolerance test should thus be performed in all CD 
patients to identify glucose metabolism abnormalities. Since diabetes mellitus (DM) is a 
consequence of cortisol excess, treating CD also serves to alleviate impaired glucose 
metabolism. Although transsphenoidal pituitary surgery remains the first-line treatment 
for CD, it is not always effective and other treatment strategies may be necessary. This 
work examines the main features of DM secondary to CD and focuses on antidiabetic 
drugs and how cortisol-lowering medication affects glucose metabolism.
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inTRODUCTiOn
Cushing’s disease (CD) is a rare pathology characterized by uncontrolled ACTH secretion from a 
pituitary adrenocorticotroph adenoma that leads to an increase in cortisol production by the adrenal 
glands (1). It is a serious condition characterized by metabolic derangements that may include visceral 
adiposity, hepatic steatosis, dyslipidaemia, and diabetes mellitus (DM) (2, 3). The prevalence of DM 
in CD patients is thought to fall between 20 and 45%, although the figure may be underestimated, 
as an oral glucose tolerance test may not be performed when a patient’s fasting glycemia is normal 
(4). Approximately 10–30% of patients have impaired glucose tolerance, and the overall prevalence 
of glucose metabolism impairments reaches nearly 70% of cases (4). No gender-related differences 
in prevalence have been noted (5). Generally speaking, the severity of hypercortisolism is correlated 
with insulin resistance and DM (6), although the correlation has not always been confirmed (7, 8). 
This discrepancy might depend on the wide inter-individual susceptibility to glucocorticoids. Age, 
genetic predisposition, and lifestyle variables combined with the duration and degree of hypercorti-
solism may all strongly contribute to glucose tolerance impairment in CD patients (9).
PATHOPHYSiOLOGY
Cortisol, which is a steroid hormone, regulates a wide range of body processes, but it displays its 
main effect after food intake. It seems to contribute to glucose intolerance and to reduce insulin 
sensitivity (10). In the liver, chronic hypercortisolism impairs fasting and postprandial glucose 
(Figure 1). Cortisol exacerbates gluconeogenesis and hepatic glucose output through both direct 
and indirect effects (4). It regulates glucocorticoid-responsive target genes by upregulating key 
FiGURe 1 | The main mechanisms of action in glucocorticoid-induced diabetes and their effects on target tissues in Cushing’s disease.
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gluconeogenic enzymes such as phosphoenolpyruvate carbox-
ykinase and glucose-6-phosphatase (4). Chronic glucocorticoid 
exposure also induces selective insulin resistance that impedes 
the inhibitory effect of insulin on hepatic glucose output (11). 
Skeletal muscles account for 70–80% of the body’s use of glucose. 
CD increases the rate of proteolysis and of muscle mass loss (12) 
with consequent decreased muscle insulin responsiveness and 
impaired glucose uptake (13). Abdominal obesity is closely associ-
ated with metabolic syndrome and CD; adipocyte-derived lipids 
in visceral adipose tissue can contribute to the onset of peripheral 
insulin resistance and DM by promoting altered insulin signaling 
in adipocytes, increased lipolysis, aberrant adipokine secretion, 
and low-grade inflammation (4). Although human studies have 
uncovered normal incretin secretion and a reduction in its 
insulin-releasing effects on β-cells, the incretin system seems 
to be affected, in animals, by hypercortisolemia since a blunted 
GLP-1 secretion has been observed in response to glucocorticoid 
administration (14, 15). Cortisol is necessary for the normal 
development of the adrenal medulla that is specialized in the syn-
thesis, storage, and secretion of catecholamines from chromaffin 
cells; its excess enhances the adrenergic-mediated increase in glu-
coneogenesis (16). Cortisol excess also has an important impact 
on GH/IGF-1 leading to an increase in visceral fat and insulin 
resistance (17, 18). Bone has also been found to be involved in 
glucose homeostasis (19); prolonged glucocorticoid exposure 
causes a reduction in circulating osteocalcin which in turn can 
enhance insulin resistance (20). Cortisol’s biological effects can be 
modulated in target tissues by the activity of 11β-hydroxysteroid 
dehydrogenase (11βHSD) enzymes; isoform 1 converts cortisone 
into cortisol, amplifying its action in the liver and adipose tis-
sue where it is primarily expressed (21). The overexpression of 
11βHSD1 in adipose tissue is correlated with the development of 
insulin resistance and obesity (22). Finally, glucocorticoid recep-
tor polymorphisms may also play a role in the development of 
metabolic complications (23). The A3669G polymorphism has 
been found to play a protective role in CD (24) by producing 
glucocorticoid resistance that increases the expression and sta-
bilization of the dominant-negative GR-β splice variant (24, 25).
THeRAPY
As diabetes is a consequence of cortisol excess, treating the under-
lying disease is unquestionably indispensable in these patients. 
Despite increasing interest in medical therapy, the first-line 
approach still remains transsphenoidal surgery (26) which pro-
vides, when it is performed by an experienced neurosurgeon, 
a mean remission rate of 77.8% (3, 27). Normalized cortisol 
levels after surgery is generally followed by an improvement 
in the patient’s glucose metabolism, but insulin resistance and 
cardiovascular risks may persist (28), particularly in patients 
with a genetic predisposition and/or persistent visceral adiposity 
(9). This means that specific, although usually at lower doses, 
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hypoglycemic treatment may be required even after remission 
following surgery (4).
AnTiDiABeTiC TReATMenT
Although correcting cortisol hypersecretion leads to an improve-
ment in glucose homeostasis, patients with CD and DM need 
to achieve glycemic control regardless of normalized cortisol 
levels. Treating diabetes in patients with CD does not essentially 
differ from treating it in ordinary circumstances (29). There are 
nevertheless some pathophysiological features that should be 
considered. Physical activity can be recommended in CD patients 
although resistance exercises should be limited in patients with 
glucocorticoid-induced myopathy (30). Metformin remains the 
first-line therapy of hyperglycemia in CD (31). While metformin 
lowers fasting plasma glucose concentrations by reducing hepatic 
glucose production (32) without causing hypoglycemia or weight 
gain (33), it may have undesired gastrointestinal side effects, that 
can be worsened by the concomitant use of pasireotide (34). 
Extended-release formulas can improve gastrointestinal toler-
ability (35). Acarbose inhibits the enzymatic cleavage of complex 
carbohydrates, delaying their absorption and thereby reducing 
postprandial glycemic excursions (36). Although it does not seem 
to have negative effects on body weight, it often produces gas-
trointestinal side effects (37). Peroxisome proliferator-activated 
receptor-γ (PPARγ) agonists interact with the nuclear receptor 
PPARγ ameliorating insulin resistance and improving hepatic 
and muscle insulin sensitivity (38). They may also potentiate the 
effects of metformin (39) on glycemic control and trigger anti-
proliferative effects on tumor cells. Pioglitazone treatment has 
not, however, been found to reduce ACTH or cortisol levels in 
CD (40, 41) and may cause weight gain and/or edema which may 
worsen the CD patient’s clinical condition (4, 42, 43).
Sulfonylureas and glinides stimulate insulin secretion in a 
glucose-independent manner triggering both the immediate 
and sustained release of insulin from intracellular granules (44). 
They are rarely used independently, but are mainly recommended 
for short-term periods to manage postprandial glycemia (45). 
Other drugs that produce good postprandial glucose control are 
dipeptidyl peptidase-4 inhibitors, which do not seem to affect 
weight (46), and since they are well tolerated, they are usually 
associated with metformin in cases of treatment intensification 
(47). GLP-1 receptor agonists act by enhancing glucose-induced 
biosynthesis and insulin secretion, inhibiting glucagon secretion, 
delaying gastric emptying, and reducing appetite (48, 49). Other 
positive effects such as weight loss and blood pressure reduction 
have also been noted (50). Incretin-based therapy may be the best 
treatment option for CD given its rapid action and positive effect 
on postprandial glycemia (51). Sodium-glucose co-transporter 
2 inhibitors are a new class of diabetic drugs (52) that cause a 
reduction in body weight and blood pressure (53). In the light of 
reports linking them to a higher risk of urinary and genital infec-
tions (54), the decision to use them should be carefully evaluated 
in CD patients who show a high risk of infections and systemic 
dissemination (55). Another possible, although rare, side effect 
that has been reported in diabetic patients is the development 
of euglycaemic ketoacidosis probably caused by an increase in 
glucagon levels and consequently enhanced ketogenesis (56). But 
given their proven capacity to improve glycemic control and their 
association to a low rate of cardiovascular events (57), their use 
should be considered in appropriate cases. Insulin may become 
necessary in patients in whom uncontrolled diabetes persists 
(29). Basal-bolus insulin therapy including basal, prandial, and 
a supplemental correction-factor insulin is considered the most 
flexible option for patients with hypercortisolism (58).
PASiReOTiDe
Pasireotide, a multi-somatostatin receptor ligand that is able 
to bind four of the five known SSTR subtypes (SSTRs1–3 and 
SSTR5) with a 40-fold greater binding affinity for SSTR5 with 
respect to octreotide (59, 60), was the first agent to be approved 
for the treatment of adult CD patients. Pasireotide has the same 
security profile of first-generation somatostatin analogs although 
it is associated with a relatively high incidence of hyperglycemia 
(61, 62) due to the expression of SSTR5 even in pancreatic β-cells 
(63). When the pathophysiology of pasireotide-induced hypergly-
cemia was investigated in healthy volunteers (64, 65), short-term 
administration was found to be followed by an increase in blood 
glucose levels associated with reduced insulin secretion (66) and 
no significant alteration in glucagon output (60). In addition, 
pasireotide can potentially reduce the secretion of other pituitary 
hormones (67). Although a decrease in the counterregulatory 
action of GH can reduce insulin resistance and hepatic gluconeo-
genesis, its deficiency can further increase metabolic complica-
tions as a result of body composition changes (68).
Clinical practice has shown that glucose alterations are more 
common and serious at the time therapy is begun but tend to sta-
bilize over time. In some cases, an improvement in glucose control 
has been reported following long-term treatment, probably as a 
result of an improvement in insulin resistance (69). Interestingly, 
pasireotide-induced hyperglycemia seems to be independent of 
the doses that are assumed (65). Besides reducing insulin secre-
tion, pasireotide also has a significant inhibitory effect on GLP-1 
and on glucose-dependent insulinotropic peptide secretion (65).
In a phase II, proof-of-concept, open-label multicenter study, 
39 patients with CD were treated with 600 µg twice daily pasire-
otide for 15  days. There was a significant reduction in urinary 
free cortisol (UFC) values in 2/3 of the patients and complete 
normalization in 17%. Hyperglycemia was found in 14 patients; 
5 of whom with a history of DM or impaired fasting glucose. 
Hyperglycemia, which was mild in most of the cases, was man-
aged with diet and oral hypoglycemic agents (61).
The effectiveness of this treatment was confirmed by a phase 
III clinical trial in which 15 and 26% of patients achieved UFC 
normalization after 6  months of treatment with, respectively, 
600 or 900 µg of pasireotide twice daily (62). Hyperglycemia was 
reported in up to 73% of cases; the rate was significantly higher 
than that observed for first-generation SST analogs. Treatment 
needed to be suspended because of uncontrolled DM in 6% of 
the patients (62). A rise in HbA1c levels from 5.8 to 7.3% was 
recorded after 12  months of pasireotide. Blood glucose and 
HbA1c levels increased rapidly after pasireotide treatment was 
begun despite a decline in cortisol levels (62).
TABLe 1 | Medications available to treat Cushing’s disease and their effects on glucose metabolism.
Drug Mechanisms of action Usual dose Hormonal 
control
Overall effect on glucose 
metabolism
effects on glucose 
metabolism
Cabergoline (75–77) Acts through D2R receptors express  
on adenocorticotroph
0.5–7 mg/week oral 25–40% ⇑ ↓ Insulin resistance
↓ Gluconeogenesis
Ketoconazole (87–90) Cholesterol side-chain cleavage complex, 
17,20-lyase, 11β-hydroxylase  
and 17α-hydroxylase inhibitor
200–1,200 mg/day ~50% ⇑ ↓ Cortisol levels
2–3 times/day, oral
Osilodrostat (97) (LCI699) 11β-hydroxylase and aldosterone  
synthase inhibitor
4–60 mg/day ~90% ⇑ ↓ Cortisol levels
2 times/day, oral
Metyrapone (93–95) 11β-hydroxylase inhibitor 0.5–6 g/day 45–75% ⇑ ↓ Cortisol levels
3–4 times/day, oral
Mifepristone (99, 100) Glucocorticoid receptor antagonist 300–1,200 mg/day Na ⇑ ↓ Cortisol effects on 
target tissuesOnce daily, oral
Mitotane (86, 98) Cholesterol side-chain cleavage complex, 
11β-hydroxylase, 18-hydroxylase and  
3β-hydroxysteroid-dehydrogenase  
inhibitor + adrenolytic action
2–5 g/day ~70% ⇑ ↓ Cortisol levels
2–3 times/day, oral
Retinoic acid (80–83) Reduces ACTH production through  
inhibition of AP-1 and Nur77/Nurrl  
transcriptional activities
10–80 mg/day 20–50% ⇑ ↓ Cortisol levels
1–3 times/day, oral ↓ Insulin resistance
↑ Insulin secretion
Pasireotide (61, 62, 65) Somatostatin multi-ligand with  
particularly high SSTR5
300–1,800 μg/day 20–50% ⇓⇓ ↓ Insulin production
Twice a day, sc ↓ Incretins secretion
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A recent phase III study examining a long-acting formulation 
of pasireotide confirmed the advantage of its convenient once-
monthly administration schedule. In addition, long-acting pasire-
otide normalized UFC in 40% of the patients and its safety profile 
was found to be similar to that of the subcutaneous formulation 
(67). Mean fasting plasma glucose and HbA1c concentrations 
increased within 1–2 months and antidiabetic medication needed 
to be initiated or adjusted in approximately in 50% of cases (67). It 
is therefore crucial to carefully check blood glucose concentrations 
in patients initiating pasireotide and to begin glucose-lowering 
therapy promptly whenever it proves necessary (47).
DOPAMine AGOniST
Since dopamine receptor agonist is able to reduce hypothalamic 
stimulation that increases during liver gluconeogenesis, lipid 
synthesis, and insulin resistance (70, 71) bromocriptine has been 
used to treat metabolic disorders associated with insulin resist-
ance and obesity (72). When cabergoline, a potent dopamine 
agonist was tested in patients with type 2 diabetes, its ability to 
reduce both fasting glycemia and HbA1c was confirmed (71). 
Cabergoline may also improve glycemic control through weight 
loss, although this effect has not been consistently found by all 
studies (73). Since dopamine D2 receptor expression was found 
in almost 80% of adenocorticotroph cells, cabergoline could be an 
efficacious treatment for CD (74); some studies have reported that 
cabergoline is effective in controlling hypercortisolism in 30–45% 
of patients (75–77). Diabetes and glucose intolerance ameliorated 
in 60 and 46%, respectively, irrespective of cortisol levels (75). 
A recent large retrospective multicenter study on 62 patients 
confirmed already published results reporting long-term cortisol 
normalization in 20–25% of cases and a significant improvement 
in glycemic control in 40% of cases (78).
ReTinOiC ACiD (RA)
After it was shown to be involved in reducing ACTH secretion 
and tumor growth in in vitro and animal models via inhibition 
of POMC expression in corticotroph tumors, RA, a nuclear 
receptor ligand, has been considered another potential option 
for CD treatment (79). The first clinical study examining its effect 
on seven CD patients demonstrated a UFC reduction ≥50% 
in five out of seven patients after 6 months of treatment and a 
complete response in three of the cases. There was a significant 
improvement in glycemia and HbA1c (decreased by 0.4–1.2%) 
in all five patients with DM at baseline (80). The 13-cis isomer 
of RA was recently examined by an open-label trial; UFC nor-
malization was reached in 4 out of the 16 patients at 12 months, 
with up to a 52% reduction in UFC in the rest. There was also 
an overall significant reduction in fasting glycemia (81). RA’s 
ameliorative effect on glucose metabolism can be attributed to 
both its cortisol-lowering action and its direct effects. In fact, 
retinol active metabolites are able to stimulate insulin secretion, 
enhance mRNA expression of glucose transporter GLUT2, and 
promote lipolysis in adipocytes by activating PPARγ (82, 83) 
(Table 1).
KeTOCOnAZOLe
Ketoconazole is an imidazole derivative that reduces adrenal ster-
oid production by inhibiting numerous steroidogenic enzymes 
(84, 85). Although it has been used for decades, no perspective 
studies are as yet available (86). At doses of 200–1,200 mg/day, it 
is able to improve glucose metabolism in CD patients (87–90). 
Ketoconazole enantiomer (DIO-902) has been found to be effec-
tive at lowering HbA1c, fasting glucose, total cholesterol levels, 
and LDL cholesterol levels (91).
5Barbot et al. Diabetes Secondary to CD
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A French study retrospectively assessed 38 CD patients receiv-
ing ketoconazole (200–1,200 mg/day) for a median of 23 months; 
the 5 patients who had DM all achieved cortisol regulation and 
an improvement in metabolic control (88). Another retrospec-
tive study examining 62 CD patients receiving steroidogenesis 
inhibitors as pre-surgical treatment (ketoconazole, metyrapone, 
or their combination) reported that HbA1C levels fell in those 
patients whose cortisol levels were entirely or partially controlled, 
but it became necessary to gradually increase insulin or prescribe 
oral antidiabetic drugs for the non-controlled patients (89).
A large retrospective multicenter study by Castinetti et  al. 
reviewing data on 200 CD patients treated with ketoconazole 
monotherapy; at baseline, 31.8% of the patients had DM. Glycemic 
control improved in more than half of the diabetic patients after 
ketoconazole therapy (90).
MeTYRAPOne
Metyrapone inhibits the final step in cortisol synthesis, namely the 
conversion of 11-deoxycortisol into cortisol by 11β-hydroxylase 
(86). Due to its rapid action, it is particularly suitable to achieve 
cortisol control within a few days’ time and thus to improve 
glucose metabolism over a short time period (92). Jeffcoate et al. 
evaluated the efficacy of metyrapone at doses ranging from 500 
to 4,000 mg/day in 13 CD patients after a mean of 21 months. Of 
the seven who had an abnormal glucose tolerance at the baseline, 
five showed improvement after 3  months of treatment (93). 
Another study reported a significant improvement in glucose 
metabolism in more than 80% of CD patients (94). Daniel et al. 
recently conducted a large retrospective study on metyrapone in 
195 CD patients, 35% of whom were diabetic. The agent’s effects 
on glucose metabolism were not analyzed by the study, but hypo-
glycemia was reported in three patients taking antidiabetic drugs 
following an improvement in hypercortisolism (95).
OSiLODROSTAT
Osilodrostat (LCI699), an adrenal steriodogenesis inhibitor deve-
loped for the treatment of CD, is currently undergoing investiga-
tion. Its mechanism of action is similar to that of metyrapone, it 
is a potent inhibitor of 11β-hydroxylase and aldosterone synthase 
(86). A 10-week, proof-of-concept study examining 12 CD 
patients receiving osilodrostat, reported no important changes in 
insulin levels, although a nearly significant decrease in HbA1c 
was noted (96).
A subsequent 22-week, multicenter, prospective, open-label, 
phase II study examined the agent’s effect on 19 CD patients. 
Although the proportion of responders reached 90% as far as 
glu cose metabolism was concerned, fasting plasma glucose and 
HbA1c levels fell from baseline to week 22; the greatest reduction 
was noted in patients with previous DM (97).
MiTOTAne
Given its strong adrenolytic effect, mitotane has been widely used 
as an adjuvant treatment for adrenal carcinoma (26). Since its 
activity is long lasting, the medication is also prescribed to patients 
with CD (86). Baudry et al. retrospectively reviewed the clinical 
charts of 76 patients from a single center who were treated with 
mitotane. Remission with a statistically significant improvement 
in both fasting and postprandial serum glucose levels was achieved 
in 48 (72%) of those receiving the drug for at least 6 months (98).
MiFePRiSTOne
Mifepristone is a glucocorticoid receptor antagonist that was 
approved by the U.S. Food and Drug Administration in 2012 for 
the treatment of hyperglycemia in CS patients who are not can-
didates for surgery (4). An open-label, multicenter, prospective, 
6-month study was conducted on 50 patients with endogenous 
CS (43 CD) who were refractory to other therapies. Study results 
showed that 29 had DM or IGT. After 24 weeks of mifepristone 
treatment, fasting plasma glucose and HbA1c decreased, respec-
tively, from 8.3 ± 4.1 to 5.8 ± 2.1 mmol/L and from 7.43 ± 1.52 to 
6.29 ± 0.99%, leading to a reduction in the number of antidiabetic 
medications the patients were taking (99). A large percentage of 
the patients showed improved insulin resistance, with the greatest 
amelioration taking place during the first 6 weeks of treatment, 
suggesting that the early rapid improvement was linked to the 
direct effects of glucocorticoid blockade, while the later one 
depended on weight loss (100).
COMBinATiOn DRUG THeRAPY
As no single drug has shown complete efficacy, combining drugs 
with additive, synergistic actions, is a strategy that has been 
used to increase the possibility of controlling hypercortisolism 
using lower doses (101) and more effectively managing glucose 
metabolism. A small prospective trial examining 14 patients with 
CD found that combining cabergoline and ketoconazole was 
more efficacious than using either of the two drugs alone, not 
only with regard to hormonal control but also as far as glucose 
metabolism was concerned (102). Other combinations such as 
the association of pasireotide-cabergoline and ketoconazole have 
also been utilized. One small trial found a complete response in 
88% of patients receiving pasireotide subcutaneously and caber-
goline. Glucose homeostasis alterations, which have been linked 
to pasireotide treatment, were, nevertheless, common (glycated 
hemoglobin level, 5.8 ± 0.2 to 6.7 ± 0.3%). Since another drug 
was being used, it was possible to use lower doses of pasireotide 
and thus to reduce its detrimental effect on glycemia (103). 
A metyrapone, ketoconazole, and mitotane combination was 
utilized in 11 patients with severe CD (4 cases of CD) as an alter-
native to rescue adrenalectomy. All the patients showed a rapid 
clinical improvement; five of the eight diabetic patients showed 
improved glycemic control (104).
COnCLUSiOn
Early diagnosis can reduce disease-related complications and 
improve life expectancy in CD patients, and DM is one of its most 
frequent although underestimated complications. Appropriate 
treatment is based on antidiabetic medication and, first and fore-
most, treating the underlying disease. Transsphenoidal surgery 
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remains the most effective treatment to control both cortisol 
and glucose metabolism as it can guarantee long-term remission 
in a high percentage of patients, but other options need to be 
considered when it is ineffective or unfeasible. With the excep-
tion of pasireotide, all cortisol-lowering medications have been 
shown to be effective in reducing to some degree the severity of 
hyperglycemia. Due to its action on peripheral insulin sensitivity, 
which is the primary mechanism responsible for glucose intoler-
ance in CD, metformin represents the mainstay of antidiabetic 
treatment. When treatment intensification becomes necessary, 
incretin-based therapies may represent a useful option. Beyond 
glucocorticoid excess, other factors implicated in DM develop-
ment such as age, genetic predisposition, and lifestyle variables 
combined with the duration and degree of hypercortisolism, may 
contribute to impaired glucose tolerance.
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